David Lee, Servier US CEO (Servier)

Once aim­ing to dou­ble on­col­o­gy pipeline, Servier's US branch touts rapid pace in build­ing its foothold in the space

The US sub­sidiary of French phar­ma Servi­er has on­ly been in ex­is­tence for a touch un­der three years, but it hasn’t wast­ed a sec­ond — snap­ping up col­lab­o­ra­tion agree­ments and oth­er deals that have pro­pelled the com­pa­ny to­ward its main goal of be­com­ing a ma­jor play­er in the on­co­log­i­cal ther­a­peu­tics in­dus­try.

David Lee, Servi­er Phar­ma­ceu­ti­cals’ CEO, told End­points News that bio­phar­ma is mak­ing a clear shift to­ward tar­get­ing can­cer ther­a­pies of all kinds, and Servi­er wants to be a part of it. Lee was named head of Servi­er’s US com­mer­cial branch when it launched in Ju­ly 2018, and his goal was am­bi­tious: dou­ble the com­pa­ny’s on­col­o­gy port­fo­lio by 2025.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.